Adjuvant chemotherapy for primary breast cancer.
For patients with hormone-unresponsive or higher-risk operable early-stage breast cancer, adjuvant chemotherapy significantly reduces the risks of relapse and death. The prognosis for such patients, especially those presenting with extensive axillary lymph node involvement, remains poor. New chemotherapy agents and novel administration schedules have recently been shown to improve clinical outcome. This overview provides a summary of the state of the art and the most recent developments regarding adjuvant chemotherapy for primary breast carcinoma.
Fornier
Monica
M
Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 457, New York, NY 10021, USA. fornierm@mskcc.org
Hudis
Clifford
C
D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D016017:Odds Ratio; D011379:Prognosis; D012008:Recurrence; D012306:Risk; D016896:Treatment Outcome
D000970:Antineoplastic Agents